Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n

PLoS Pathogens

Volumn 8, Issue 7, 2012, Pages 39-

  Refsland, Eric W ^a,b,c,d   Hultquist, Judd F ^a,b,c,d   Harris, Reuben S ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN; APOBEC3F PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; SMALL INTERFERING RNA;

ARTICLE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; T LYMPHOCYTE; CELL STRAIN HEK293; CYTOLOGY; GENETIC VARIABILITY; GENETICS; HUMAN; METABOLISM; MUTAGENESIS; PHYSIOLOGY; REGULATOR GENE; RNA INTERFERENCE; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; GENES, VIF; GENETIC VARIATION; HEK293 CELLS; HIV-1; HUMANS; MUTAGENESIS; MUTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84864576348     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002800     Document Type: Article

References (59)

1. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474-9485.
2. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274-4284.
3. Albin JS, Harris RS, (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12: e4.
4. Malim MH, Emerman M, (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3: 388-398.
5. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
6. Yu Q, König R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
7. Caride E, Brindeiro RM, Kallas EG, de Sa CA, Eyer-Silva WA, et al. (2002) Sexual transmission of HIV-1 isolate showing G→A hypermutation. J Clin Virol 23: 179-189.
8. Fitzgibbon JE, Mazar S, Dubin DT, (1993) A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses 9: 833-838.
9. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82: 3125-3130.
10. Janini M, Rogers M, Birx DR, McCutchan FE, (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75: 7973-7986.
11. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
12. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396.
13. Liddament MT, Brown WL, Schumacher AJ, Harris RS, (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14: 1385-1391.
14. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR, (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23: 2451-2458.
15. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78: 6073-6076.
16. Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, et al. (2010) Stably expressed APOBEC3F has negligible antiviral activity. J Virol 84: 11067-11075.
17. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84: 9613-9617.
18. Albin JS, Haché G, Hultquist JF, Brown WL, Harris RS, (2010) Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol 84: 10209-10219.
19. Haché G, Shindo K, Albin JS, Harris RS, (2008) Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol 18: 819-824.
20. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity to Restrict Vif-deficient HIV-1. J Virol 85: 11220-34.
21. Mariani R, Chen D, Schrofelbauer B, Navarro F, König R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
22. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, et al. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol 81: 13346-13353.
23. Schumacher AJ, Haché G, MacDuff DA, Brown WL, Harris RS, (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol 82: 2652-2660.
24. Wissing S, Montano M, Garcia-Perez JL, Moran JV, Greene WC, (2011) Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem 286: 36427-36437.
25. Kamata M, Nagaoka Y, Chen IS, (2009) Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog 5: e1000342.
26. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, et al. (2011) APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 7: e1002221.
27. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, et al. (1965) Continuous Culture of Human Lymphoblasts from Peripheral Blood of a Child with Acute Leukemia. Cancer 18: 522-529.
28. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
29. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, et al. (1992) Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 66: 6489-6495.
30. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP, (2005) Recovery of APOBEC3-edited human immunodeficiency virus G→A hypermutants by differential DNA denaturation PCR. J Gen Virol 86: 125-129.
31. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
32. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
33. Virgen CA, Hatziioannou T, (2007) Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J Virol 81: 13932-13937.
34. Fabian MR, Sonenberg N, Filipowicz W, (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
35. Dang Y, Abudu A, Son S, Harjes E, Spearman P, et al. (2011) Identification of a single amino acid required for APOBEC3 antiretroviral cytidine deaminase activity. J Virol 85: 5691-5695.
36. Dang Y, Wang X, Esselman WJ, Zheng YH, (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80: 10522-10533.
37. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79: 1975-1980.
38. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, et al. (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82: 8172-8182.
39. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, et al. (2008) Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376: 101-111.
40. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J, (2009) Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 83: 7805-7814.
41. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M, (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4: 249-259.
42. Wang X, Abudu A, Son S, Dang Y, Venta PJ, et al. (2011) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol 85: 3142-3152.
43. Ooms M, Majdak S, Seibert CW, Harari A, Simon V, (2010) The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J Virol 84: 7961-7969.
44. LaRue RS, Lengyel J, Jónsson SR, Andrésdóttir V, Harris RS, (2010) Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol 84: 8193-8201.
45. Li MM, Wu LI, Emerman M, (2010) The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol 84: 88-95.
46. Zhen A, Wang T, Zhao K, Xiong Y, Yu XF, (2010) A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol 84: 1902-1911.
47. Aguiar RS, Lovsin N, Tanuri A, Peterlin BM, (2008) Vpr.A3A chimera inhibits HIV replication. J Biol Chem 283: 2518-2525.
48. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR, (2006) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 34: 89-95.
49. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K, (2007) Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4: 61.
50. Marin M, Golem S, Rose KM, Kozak SL, Kabat D, (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol 82: 987-998.
51. Yu Q, Chen D, König R, Mariani R, Unutmaz D, et al. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 279: 53379-53386.
52. Doehle BP, Schäfer A, Cullen BR, (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339: 281-288.
53. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, et al. (2006) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A 103: 8780-8785.
54. Langlois MA, Beale RC, Conticello SG, Neuberger MS, (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 33: 1913-1923.
55. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS, (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 17: 222-229.
56. Rose KM, Marin M, Kozak SL, Kabat D, (2005) Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res Hum Retroviruses 21: 611-619.
57. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1: e6.
58. Russell RA, Pathak VK, (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81: 8201-8210.
59. Rago C, Vogelstein B, Bunz F, (2007) Genetic knockouts and knockins in human somatic cells. Nat Protoc 2: 2734-2746.